- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07941843
Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer (LF-FOLFOX)
The Probability of a Protective Effect of Lactoferrin on FOLFOX-Related Toxicities in Colorectal Cancer
This randomized controlled clinical trial aims to investigate the potential protective effects of oral lactoferrin supplementation against chemotherapy-related toxicities in patients with colorectal cancer receiving the FOLFOX regimen.
A total of 44 eligible adult patients will be randomly allocated into two parallel groups (22 patients per group). The control group will receive standard FOLFOX chemotherapy, while the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin (Pravotin) at a dose of 100 mg twice daily, starting from the first chemotherapy cycle and continuing throughout the planned chemotherapy course.
The study will evaluate peripheral neuropathy, gastrointestinal and hematological toxicities, oxidative stress and neuroprotective biomarkers.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Colorectal cancer is commonly treated with oxaliplatin-based chemotherapy regimens such as FOLFOX, which combines oxaliplatin, 5-fluorouracil, and leucovorin. Despite its therapeutic effectiveness, FOLFOX is associated with peripheral neuropathy, gastrointestinal toxicity, hematological abnormalities, and impaired quality of life.
Lactoferrin is an iron-binding glycoprotein with antioxidant, anti-inflammatory, immunomodulatory, and potential neuroprotective properties. These biological activities may help mitigate chemotherapy-induced toxicities.
This study will investigate the potential protective effects of lactoferrin supplementation in 44 patients with histologically confirmed colorectal cancer who are scheduled to receive at least six cycles of FOLFOX chemotherapy at Damanhour Oncology Center.
Eligible participants will be randomly assigned in a 1:1 ratio to receive either standard FOLFOX chemotherapy alone or standard FOLFOX chemotherapy combined with oral lactoferrin 100 mg twice daily.
Participants will undergo clinical evaluations, laboratory monitoring, and assessment of chemotherapy-related adverse events. Laboratory investigations will include complete blood count, kidney and liver function tests, and serum biomarkers including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and malondialdehyde (MDA).
Clinical assessments and laboratory investigations will be conducted during chemotherapy, with final assessments at the completion of the planned chemotherapy course.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Toka M El-Banna, Clinical pharmacy TA
- Telefonnummer: 00201018546392
- E-post: tokaelbanna@gmail.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adult patients aged 18 years or older with histologically confirmed colorectal cancer.
- Patients scheduled to receive at least six cycles of FOLFOX chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Exclusion Criteria:
- Pre-existing peripheral neuropathy of grade 1 or higher.
- Hereditary neuromuscular disorders.
- Advanced liver disease, defined as liver enzymes greater than three times the upper limit of normal or established cirrhosis.
- Chronic kidney disease with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m².
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Standard FOLFOX Chemotherapy
Participants assigned to the control group will receive standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin according to the routine oncology treatment protocol. |
Standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin, administered according to the treating oncology center's standard protocol. |
|
Experimentell: FOLFOX Plus Lactoferrin
Participants assigned to the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin supplementation (Pravotin) at a dose of 100 mg twice daily, initiated at the first chemotherapy cycle and continued throughout the planned chemotherapy course. |
Standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin, administered according to the treating oncology center's standard protocol. Oral lactoferrin supplementation (Lactomash), administered at a dose of 100 mg twice daily (total daily dose: 200 mg), starting from the first FOLFOX chemotherapy cycle and continuing throughout the planned chemotherapy course. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of Oxaliplatin-Induced Peripheral Neuropathy
Tidsram: From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.
|
Proportion of participants developing peripheral neuropathy during FOLFOX chemotherapy, assessed and graded according to biomarkers. |
From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- - Macciò A, et al. The Oncologist. 2010
- Lesser GJ, Irby MB, Taylor RC, Snavely A, Case D, Wang A, Dietrich A, Duncan S. Lactoferrin supplementation for taste and smell abnormalities among patients receiving cancer chemotherapy. Support Care Cancer. 2022 Mar;30(3):2017-2025. doi: 10.1007/s00520-021-06609-8. Epub 2021 Oct 13.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Tarmsjukdomar
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Kolonsjukdomar
- Kolorektala neoplasmer
- Aminosyror, peptider och proteiner
- Proteiner
- Kolhydrater
- Hydrolaser
- Enzymer
- Enzymer och koenzymer
- Globuliner
- Glykoprotiner
- Glykokonjugat
- Endopeptidaser
- Peptidhydrolaser
- Serin endopeptidaser
- Serinproteaser
- Dietproteiner
- Mjölkproteiner
- Animaliska proteiner, kost
- Bärarproteiner
- Transferrins
- Järnbindande proteiner
- Laktoglobuliner
- Vassleproteiner
- Metalloproteiner
- Laktoferrin
- Folfoxprotokoll
Andra studie-ID-nummer
- LF-FOLFOX-CRC-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Individual participant data (IPD) will not be shared.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .